Logo

Gilead Collaborates with EVOQ Therapeutics to Advance Immunotherapies in Rheumatoid Arthritis and Lupus

Share this
Gilead, EVOQ Therapeutics

Gilead Collaborates with EVOQ Therapeutics to Advance Immunotherapies in Rheumatoid Arthritis and Lupus

Shots:

  • Through preclinical collaboration and licensing agreement, Gilead has the option to license rights to develop and commercialize products for autoimmune diseases by using EVOQ’s NanoDisc technology
  • Under the agreement, EVOQ will receive ~$658.5M incl. upfront, option exercise, and milestone payments across all programs, as well as tiered royalties on product sales
  • NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens to restore immune tolerance

Ref: Businesswire | Image: Gilead 

Related News:- Edwards Presents (TRISCEND) Study Results of EVOQUE Transfemoral Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation at PCR 2022

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions